Drug Discovery World

AUGUST 22, 2023

This will continue to be the case going forward, but the nature of the off-patent landscape will evolve in line with ongoing changes in the segment’s ‘pipeline’: the originator products of today, which will become the generic and biosimilar medicines of tomorrow. What are complex generics?

Production 52

Production Bioequivalency In-Vivo In-Vitro 52

pharmaphorum

AUGUST 24, 2020

She served as the Deputy Director (Acting) in the Office of Process and Facilities (OPF)/OPQ/CDER, responsible for new, generic, and biologic drug product quality review and facility assessment. Monocyte Activation Test: The In-vitro Pyrogen Test Based on Human Immune Cells for Batch Release Testing of Medical Products.

Contamination 52

Contamination In-Vitro Production Containment 52

XTalks

SEPTEMBER 14, 2020

In the meantime, WHO Director-General, Tedros Ghebreyesus feels that “vaccine nationalism” may prove to be the undoing of the potential to halt the spread of COVID-19. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

The Pharma Data

MAY 4, 2021

Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 Billion and Adjusted Diluted EPS (2) to a Range of $3.55 Now Anticipates Revenues of Approximately $26 Billion for BNT162b2, Reflecting 1.6 Billion Doses Expected to be Delivered in 2021 Under Signed Contracts as of Mid-April 2021. per share amounts). Reported Diluted EPS (1).

Vaccination 40

Vaccination Vaccine Production Sales 40